Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT03817216 Withdrawn - Prostate Cancer Clinical Trials

Prostatic Urethral Lift (PUL) Pre-/Post-Radiation Treatment for Prostate Cancer

Start date: December 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to test the use of the Prostatic Urethral Lift (PUL), Urolift®, in prostate cancer (Pca) participants seeking or undergoing radiotherapy for relief of urinary obstructive symptoms.

NCT ID: NCT03800784 Withdrawn - Prostate Cancer Clinical Trials

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

Start date: October 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This study evaluates the rate of radiological disease progression with the new 2nd generation positron emission tomography (PET) radiopharmaceutical, 18F-DCFPyL, in patients with metastatic castration (mCRPC) and non-metastatic (nmCRPC) castration resistant prostate cancer who have evidence of biochemical (PSA) disease progression without evidence of radiological disease progression on conventional standard radiologic testing (99mTc-methylene diphosphonate bone scan and CT).

NCT ID: NCT03748719 Withdrawn - Prostate Cancer Clinical Trials

Single Arm Trial of Preoperative Stereotactic Body Radiation Therapy (SBRT) for T3a or Gleason Grade Group 4 Prostate Cancer

Start date: November 19, 2018
Phase: N/A
Study type: Interventional

This study involves Stereotactic Body Radiation Therapy (SBRT) followed by prostatectomy (removal of the prostate). SBRT is a relatively new radiation technique in which a few doses of radiation are delivered to small, well-defined tumors. It has been used effectively in other cancers like lung and liver. The radiation will be given for only 5 days. The purpose of this study is to compare the effects, good and/or bad, of different doses of SBRT given before prostatectomy.

NCT ID: NCT03589781 Withdrawn - Prostate Cancer Clinical Trials

Investigating the Effects of Mikei® Red Reishi Essence EX on the Immune System of Prostate Cancer Patients and Patients With Non-cancerous Conditions of the Prostate

Start date: November 5, 2020
Phase: N/A
Study type: Interventional

The primary objective of this study is to determine the effects of Mikei® Red Reishi Essence EX extract powder on the immune function of prostate cancer patients and patients with non-cancerous conditions of the prostate.

NCT ID: NCT03495479 Withdrawn - Prostate Cancer Clinical Trials

Aneustat Treatment of Localized Prostate Cancer Under Active Surveillance

CAMPAS
Start date: January 2025
Phase:
Study type: Observational

Assessment of the effects of OMN54 (Aneustat) in a population of men with indolent prostate cancer who are otherwise healthy and free of significant co-morbidities and have chosen active surveillance for disease management. The investigators will assess how OMN54 affects PSA, overall tumor burden in addition to any changes in urinary flow. Other biomarkers will be tested to follow disease evolution.

NCT ID: NCT03494803 Withdrawn - Prostate Cancer Clinical Trials

Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC

Start date: June 1, 2018
Phase:
Study type: Observational

Prostate cancer is a leading cause of mortality and morbidity. The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC, T-cells and circulated tumor DNA in prostate cancer patients.

NCT ID: NCT03488810 Withdrawn - Prostate Cancer Clinical Trials

Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer

ARN-509
Start date: March 10, 2020
Phase: Phase 3
Study type: Interventional

The main objective of the trial to determine if the combination of apalutamide with 6 months of androgen deprivation therapy by LHRH agonists in patients with intermediate and limited high-risk, localized prostate cancer receiving primary radiation therapy (RT) results in an improvement of disease-free survival (DFS) evaluated by the treating physician, in comparison to the combination of radiation and androgen deprivation therapy without the addition of apalutamide.

NCT ID: NCT03465345 Withdrawn - Prostate Cancer Clinical Trials

Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients

Start date: July 11, 2018
Phase: Phase 1
Study type: Interventional

The overall goal of this study is to identify a safe dose of metformin, in combination with oligomeric procyanidin complex (OPC) for pharmacologic reduction of AGE levels in patients with prostate cancer.

NCT ID: NCT03459755 Withdrawn - Prostate Cancer Clinical Trials

Evaluating Race Specific AGE Accumulation as a Behavioral Biomarker Prostate Cancer Survivors

Start date: November 27, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to show that reduction in advanced glycation end-products (AGEs) is associated with the beneficial regulation of receptor for AGE (RAGE) mediated tumor response which may correlate with improved quality of life in PCa survivors. AGEs are produced by the body and are affected by lifestyle, weight and diet.

NCT ID: NCT03338712 Withdrawn - Prostate Cancer Clinical Trials

Micro-RNA Expression Profiles in Localised Prostate Cancer

Start date: February 1, 2010
Phase: N/A
Study type: Observational

Recurrence free survival The patients will be followed in regular time intervals in accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the German Urological Association. Data will be updated once yearly for until death.